Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

被引：13
|
作者：
Rimassa, Lorenza
Cicin, Irfan
Blanc, Jean-Frederic
Klumpen, Heinz Josef
Zagonel, Vittorina
Tran, Albert
Kim, Stefano Chong Hun
Lin, Zhong-Zhe
Tam, Vincent C.
Hazra, Saswati
Mangeshkar, Milan
El-Khoueiry, Anthony
Cheng, Ann-Lii
Meyer, Tim
Kelley, Robin Kate
Abou-Alfa, Ghassan K.
机构：
[1] Humanitas Clin & Res Ctr, Rozzano, Italy
[2] Trakya Univ, Fac Med, Dept Med Oncol, Edirne, Turkey
[3] Grp Hosp St Andre, Serv Hepato Gastroenterol & Oncol Digest, Bordeaux, France
[4] Univ Amsterdam, Acad Med Ctr, Dept Clin Oncol, Amsterdam, Netherlands
[5] Ist Oncol Veneto, IRCCS, Padua, Italy
[6] Grp Hosp Archet, Nice, France
[7] Univ Besancon, Ctr Hosp, Besancon, France
[8] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[9] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[10] Exelixis Inc, San Francisco, CA USA
[11] USC, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[12] Natl Taiwan Univ Hosp, Taipei, Taiwan
[13] UCL, Canc Inst, London, England
[14] Univ Calif San Francisco, San Francisco, CA 94143 USA
[15] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4090
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Venerito, M.
    Rimassa, L.
    Cicin, I
    Blanc, J-F
    Kluempen, H-J
    Zagonel, V
    Tran, A.
    Kim, S.
    Lin, Z-Z
    Tam, V. C.
    Hazra, S.
    Mangeshkar, M.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 283 - 283
  • [2] Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Yau, T.
    Cheng, A-L.
    Meyer, T.
    Ryoo, B-Y.
    Park, J-W.
    Klumpen, H-J.
    Lim, H. Y.
    Kim, S.
    Knox, J.
    Patel, M.
    El-Khoueiry, A. B.
    Kelley, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Alpha Fetoprotein (AFP) Response and Efficacy Outcomes in the Phase 3 Celestial Trial of Cabozantinib (C) Versus Placebo (P) in Advanced Hepatocellular Carcinoma (HCC)
    Waidmann, Oliver
    Kelley, R. K.
    Rimassa, L.
    Ryoo, B. Y.
    Blanc, J. F.
    Chan, S. L.
    Zagonel, V.
    Yau, T.
    Sen, S.
    Markby, D. W.
    Kaldate, R.
    El-Khoueiry, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 59 - 59
  • [4] Alpha fetoprotein (AFP) response and efficacy outcomes in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Venerito, M.
    Kelley, R. K.
    Rimassa, L.
    Ryoo, B. -Y.
    Blanc, J. -F.
    Chan, S. L.
    Zagonel, V.
    Yau, T.
    Sen, S.
    Markby, D. W.
    Kaldate, R.
    El-Khoueiry, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 125 - 125
  • [5] Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
    Parnis, F.
    Rimassa, L.
    Kelley, R. K.
    Meyer, T.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Blanc, J. F.
    Lim, H-Y
    Tran, A.
    Borgman-Hagey, A. E.
    Clary, D. O.
    Wang, E.
    Cheng, A-L
    El-Khoueiry, A. B.
    Abou-Alfa, G. K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 180 - 181
  • [6] Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Blanc, J. F.
    Meyer, T.
    Cheng, A-L.
    El-Khoueiry, A. B.
    Cicin, I.
    Chen, Y.
    Bolondi, L.
    Dadduzio, V.
    Baron, A.
    Lin, Z-Z.
    Adriani, J.
    Kelly, R. K.
    Abou-Alfa, G. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 237 - 237
  • [7] Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
    Rimassa, Lorenza
    Kelley, Robin Kate
    Meyer, Tim
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Blanc, Jean-Frederic
    Lim, Ho Yeong
    Tran, Albert
    Chan, Yi-Wah
    McAdam, Paul
    Wang, Evelyn
    Cheng, Ann-Lii
    El-Khoueiry, Anthony B.
    Abou-Alfa, Ghassan K.
    LIVER CANCER, 2021, : 38 - 47
  • [8] Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Venerito, M.
    Kelley, R. K.
    Ryoo, B-Y
    Merle, P.
    Park, J-W
    Bolondi, L.
    Chan, S. L.
    Lim, H. Y.
    Baron, A.
    Parnis, F.
    Knox, J.
    Cattan, S.
    Yau, T.
    Lougheed, J. C.
    Milwee, S.
    El-Khoueiry, A. B.
    Cheng, A-L
    Meyer, T.
    Abou-Alfa, G. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 282 - 283
  • [9] Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).
    Kelley, Robin Kate
    Ryoo, Baek-Yeol
    Merle, Philippe
    Park, Joong-Won
    Bolondi, Luigi
    Chan, Stephen Lam
    Lim, Ho Yeong
    Baron, Ari David
    Parnis, Francis
    Knox, Jennifer
    Cattan, Stephane
    Yau, Thomas Cheung
    Lougheed, Julie
    Milwee, Steven
    El-Khoueiry, Anthony
    Cheng, Ann-Lii
    Meyer, Tim
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial
    Waidmann, O.
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A-L
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B-Y
    Cicin, I
    Merle, P.
    Chen, Y. H.
    Park, J-W
    Blanc, J-F
    Bolondi, L.
    Klumpen, H-J
    Chan, S. L.
    Dadduzio, V
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 254 - 254
12345